

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Valchlor Prior Authorization Policy

- Valchlor® (mechlorethamine topical gel – Helsinn)

REVIEW DATE: 12/13/2023

OVERVIEW

Valchlor, a nitrogen mustard, is indicated for the topical treatment of Stage IA and IB **mycosis fungoides-type cutaneous T-cell lymphoma** in patients who have received prior skin-directed therapy.¹

Guidelines

Valchlor is addressed in National Comprehensive Cancer Network guidelines:

- **Histiocytic neoplasms:** Guidelines (version 1.2023 – August 11, 2023) recommend Valchlor for the topical treatment of unifocal Langerhans cell histiocytosis with isolated skin disease.^{2,5}
- **Primary cutaneous lymphomas:** Guidelines (version 1.2023 – January 5, 2023) recommend Valchlor for the topical treatment of primary cutaneous B-cell lymphoma, mycosis fungoides/Sezary syndrome, and primary cutaneous CD30+ T-cell lymphoproliferative disorders.^{2,3}
- **T-cell lymphomas:** Guidelines (version 1.2023 – January 5, 2023) recommend Valchlor for the topical treatment of adult T-cell leukemia/lymphoma – chronic/smoldering subtype.^{2,4}

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Valchlor. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Valchlor is recommended in those who meet one of the following criteria:

FDA-Approved Indication

1. **Cutaneous Lymphomas.** Approve for 1 year if the patient is ≥ 18 years of age.
Note: Includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders.

Other Uses with Supportive Evidence

2. **Adult T-Cell Leukemia/Lymphoma.** Approve for 1 year if the patient has chronic/smoldering subtype of adult T-cell leukemia/lymphoma.
3. **Langerhans Cell Histiocytosis.** Approve for 1 year if, according to the prescriber, patient has unifocal Langerhans cell histiocytosis with isolated skin disease.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

12/13/2023

© 2023. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Coverage of Valchlor is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Valchlor® topical gel [prescribing information]. Iselin, NJ: Helsinn; January 2020.
2. The NCCN Drugs and Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 8, 2023. Search term: mechlorethamine.
3. The NCCN Primary Cutaneous Lymphomas Clinical Practice Guidelines in Oncology (version 1.2023 – January 5, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 8, 2023.
4. The NCCN T-Cell Lymphomas Clinical Practice Guidelines in Oncology (version 1.2023 – January 5, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 8, 2023.
5. The NCCN Histiocytic Neoplasms Clinical Practice Guidelines in Oncology (version 1.2023 – August 11, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed December 8, 2023.